Imperial College London
Alternate

Emeritus ProfessorRobertSinden

Faculty of Natural Sciences, Department of Life Sciences

Emeritus Professor of Parasite Cell Biology
 
 
 
//

Contact

 

r.sinden Website

 
 
//

Location

 

2.1Centre for Population BiologySilwood Park

//

Summary

 

Publications

Citation

BibTex format

@article{Marques:2016:10.1016/j.nano.2016.09.010,
author = {Marques, J and Valle-Delgado, JJ and Urbán, P and Baró, E and Prohens, R and Mayor, A and Cisteró, P and Delves, M and Sinden, RE and Grandfils, C and de, Paz JL and García-Salcedo, JA and Fernàndez-Busquets, X},
doi = {10.1016/j.nano.2016.09.010},
journal = {Nanomedicine: Nanotechnology, Biology and Medicine},
title = {Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery.},
url = {http://dx.doi.org/10.1016/j.nano.2016.09.010},
year = {2016}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as an heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.
AU  - Marques,J
AU  - Valle-Delgado,JJ
AU  - Urbán,P
AU  - Baró,E
AU  - Prohens,R
AU  - Mayor,A
AU  - Cisteró,P
AU  - Delves,M
AU  - Sinden,RE
AU  - Grandfils,C
AU  - de,Paz JL
AU  - García-Salcedo,JA
AU  - Fernàndez-Busquets,X
DO  - 10.1016/j.nano.2016.09.010
PY  - 2016///
SN  - 1549-9634
TI  - Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery.
T2  - Nanomedicine: Nanotechnology, Biology and Medicine
UR  - http://dx.doi.org/10.1016/j.nano.2016.09.010
ER  -
Download